Geode Capital Management LLC grew its stake in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Free Report) by 3.3% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 1,355,392 shares of the company’s stock after buying an additional 43,856 shares during the period. Geode Capital Management LLC owned approximately 1.08% of Karyopharm Therapeutics worth $1,125,000 as of its most recent filing with the SEC.
Several other hedge funds have also made changes to their positions in the stock. FMR LLC grew its holdings in shares of Karyopharm Therapeutics by 26.1% during the 3rd quarter. FMR LLC now owns 369,723 shares of the company’s stock worth $307,000 after purchasing an additional 76,510 shares in the last quarter. GSA Capital Partners LLP raised its stake in shares of Karyopharm Therapeutics by 80.6% in the 3rd quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company’s stock valued at $1,474,000 after buying an additional 792,283 shares in the last quarter. Exchange Traded Concepts LLC lifted its holdings in shares of Karyopharm Therapeutics by 34.9% during the 3rd quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock worth $182,000 after acquiring an additional 56,613 shares during the period. Point72 DIFC Ltd acquired a new stake in shares of Karyopharm Therapeutics during the 2nd quarter valued at about $31,000. Finally, Cubist Systematic Strategies LLC bought a new stake in Karyopharm Therapeutics in the second quarter valued at about $494,000. Institutional investors own 66.44% of the company’s stock.
Karyopharm Therapeutics Price Performance
KPTI stock opened at $0.72 on Friday. The business has a fifty day moving average price of $0.78 and a 200 day moving average price of $0.82. Karyopharm Therapeutics Inc. has a fifty-two week low of $0.58 and a fifty-two week high of $1.95. The stock has a market capitalization of $90.35 million, a price-to-earnings ratio of -0.63 and a beta of 0.07.
Wall Street Analysts Forecast Growth
A number of research firms have weighed in on KPTI. StockNews.com downgraded Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 22nd. Piper Sandler upped their price target on Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a research report on Wednesday, November 6th. Finally, HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Karyopharm Therapeutics in a report on Friday, November 1st. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Karyopharm Therapeutics has an average rating of “Moderate Buy” and an average target price of $5.00.
View Our Latest Research Report on Karyopharm Therapeutics
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
Recommended Stories
- Five stocks we like better than Karyopharm Therapeutics
- What is the Euro STOXX 50 Index?
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- 5 Top Rated Dividend Stocks to Consider
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.